Filed by Consonance-HFW Acquisition Corp.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934
Subject Company: Consonance-HFW Acquisition Corp.
Commission File No. 001-39635
Surrozen Presents New Data Demonstrating Superior Activity of
in Preclinical Inflammatory
Bowel Disease Models at 16th Congress of the European Crohns and Colitis Organisation (ECCO)
Company to advance
clinical studies in 2022
SOUTH SAN FRANCISCO, Calif.,
July 09, 2021 (GLOBE NEWSWIRE) Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that new data from its inflammatory bowel disease (IBD) program,
including preclinical studies of
showing superior activity compared to therapeutics currently used in treatment, were presented during the
Congress of the European Crohns and Colitis Organisation.
Two poster presentations
discussed data from studies of
full-length human anti
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Consonance-HFW Acquisition Corp. makes a similar move, sign up!
Other recent filings from the company include the following: